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Purpose. To compare the therapeutic results of two radiotherapy (RT) dose schedules in combined temozolomide- (TMZ-)
RT treatment in newly diagnosed glioblastoma (GB), according to the O(6)-methylguanine-DNA methyltransferase (MGMT)
methylation status. Material and Method. Patients received either standard (60Gy) or moderately escalated dose (70Gy)
radiotherapy (RT) with concomitant and adjuvant TMZ between June 2006 and October 2013. We retrospectively evaluated the
therapeutic effectiveness of RT schedules in terms ofOverall Survival (OS) and Progression-Disease Free Survival (PDFS) analyzing
the MGMT methylation status. Results. One hundred and seventeen patients were selected for the present analysis. Seventy-two
out of the selected cases received the standard RT-TMZ course (SDRT-TMZ) whereas the remaining 45 underwent the escalated
schedule (HDRT-TMZ).The analysis according to the MGMT promoter methylation status showed that, in unmethylated-MGMT
GB patients, HDRT-TMZ and SDRT-TMZ groups had different median OS (𝑝 = 0,01) and PDFS (𝑝 = 0,007), that is, 8 months and
5 months for the SDRT-TMZ group and 14 months and 9 months for the HDRT-TMZ group, respectively. No difference in survival
outcomes was found in methylated MGMT patients according to the two RT schedules (𝑝 = 0,12). Conclusions. In our experience,
unmethylated-MGMT GB patients benefited from a moderately escalated dose of RT plus TMZ.
1. Introduction
Glioblastoma is the most frequent primary brain tumor
(≥50% out of all the cases of primary tumors in the brain)
with an incidence of about five new cases per 100,000 per year.
Despite aggressive multimodal treatments, the prognosis of
this disease remains poor with 5-year survival outcomes
barely reaching 5%. Postsurgery RT plus TMZ chemotherapy
is presently the backbone of the management of patients
affected by GB [1].
A wide characterization of GB by multiple omics plat-
forms has recently improved our knowledge of the molecular
bases underlying GB aggressiveness [2, 3]. Nevertheless, in
the clinical setting only the methylation status of the O(6)-
methylguanine-DNA methyltransferase (MGMT) promoter,
that is, a DNA repair enzyme that causes resistance to alky-
lating agents such as TMZ [4, 5], plays a practical role. The
MGMT promoter methylation positive status has a highly
significant predictive role of response to TMZ combined
with RT [1, 5], whereas unmethylated MGM is considered
an inherent prognostic indicator for patients with GB with
a particularly poor survival [6, 7]. However, a more limited
positive impact on survival results of the RT and TMZ
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combinationwas demonstrated also for these last patients [5].
More aggressive approaches may therefore be warranted for
the latter category, even if those including very intensive TMZ
administration failed to show a survival advantage [8]. We
could not find any contribution particularly dealing with RT
intensification.The present analysis is addressed to this topic,
retrospectively comparing patients treated in our institution
with a moderate RT dose escalation (70Gy) plus TMZ [9]
with those undergoing standardRT (60Gy) plus TMZ, taking
into account the MGMTmethylation status.
2. Material and Method
We obtained ethics approval of the study and a signed
informed consent by each patient for the anonymous use
of clinical and treatment data. All the adopted procedures
were in accordance with the ethical standards of the Helsinki
Declaration (1964, amended most recently in 2008) of the
World Medical Association.
2.1. Patient Series. We analyzed themedical records from our
institutional brain tumor database containing 222 patients
affected by GB (Grade IV–WHO Classification [10]), con-
secutively referred to the Radiation Oncology Unit for
postoperative RT-TMZ, after the pathologic diagnosis (CM),
from February 2007 to July 2014. The MGMT gene promoter
methylation status was assessed using a methylation-specific
Polymerase Chain Reaction (PCR), as previously reported
[11]. Briefly, genomic DNA was extracted from paraffin-
embedded tumor sections and treated with sodium bisulfite
using the EZ DNA Methylation-Gold kit (HISS Diagnostics,
GmbH, Freiburg, Germany). Primer sequences were used
to detect methylated and unmethylated MGMT promoter
sequences. PCR products were separated on 2% agarose gel.
A glioma cell line with a completely methylated MGMT
promoter and peripheral blood mononucleated cells served
as positive and negative control samples, respectively. A
methylation percentage of 5% was used as a cut-off value:
samples with methylation < 5% and >5% were classified as
unmethylated and methylated, respectively.
2.2. Extent of Surgical Resection. The extent of surgical resec-
tion was obtained by the description of surgical procedures
and the postoperative CT-MR imaging (72 h and 30 days
after surgery) and classified as follows: biopsy (B), subtotal
resection (STR), and gross total resection (GTR).
2.3. Selection Criteria. Only patients with unifocal GB have
been considered for the present evaluation. All patients
undergoing palliative whole brain irradiation for multifocal
or very large GBs and with a Karnofsky Performance Status
(KPS) score below 70% were excluded. Further, only patients
whose Planning Target Volume (PTV, ≤115ml) was compat-
ible with the constraints we adopt for a boost up to 70Gy,
according to the previously published institutional protocol
[9], were included in this study. Clinical and pathological
data, including extent of surgery, prior to RT start, the base-
line MRI (i.e., preresection or biopsy) study, were available
in all cases. The MRI scan was obtained with a standard
protocol, as follows: T1, T2, and FLAIR (Fluid Attenuated
Inversion Recovery) acquisitions, DWI (Diffusion-Weighted
Imaging) axial sequences (5mm slices thickness/5.5mm
separation), and T1-gadolinium-enhanced scans, in axial,
coronal, and sagittal planes. After the repetition of this
exam before irradiation, all patients initiated the RT-TMZ
adjuvant treatment within 4–8 weeks after surgery, according
to the protocol defined by Stupp et al. [1]. The patients
received either standard dose treatment (SDRT: 59,4–60Gy)
or moderate dose escalation (HDRT: 69,4–70Gy) according
to the selection criteria specified above. They were assigned
to one or the other of these schedules based on the clinical
judgement of the responsible radiation oncologists (PT, VN,
PP, GB, LS, and GR) mainly taking into account the volume
and the region of the lesion (Figures 1(a) and 1(b)) and
adjacency to critical brain regions.
2.4. Radiotherapy Treatment Planning
SDRT: 59,4–60Gy. The Clinical Target Volume (CTV) was
contoured on CT and postoperative MRI image fusion and
included residual tumor mass (T1 gadolinium-enhanced
lesion) and/or postoperative cavity (i.e., GTV) plus a
15–20mm margin without consideration for peritumoral
edema. Volume contouring took into account anatomical
barriers, such as ventricular spaces, cranial bones, and the
midline except for the region of the corpus callosum. An
isotropic margin of 5mm was added around to obtain the
Planning Target Volume (PTV-1). RT was delivered with
a Linear Accelerator 6–10MeV beam and 3D-Conformal
or Intensity Modulated techniques up to a planned total
dose of at least 59,4Gy and with a standard fractionation
(1,8–2Gy/day for 5 days per week).
HDRT: 69,4–70Gy. A dose boost up to 69,4–70Gy was
delivered to the selected cases, as defined above, according
to the previously published institutional protocol, respecting
OAR constraints in CNS [12]. Briefly, in patients without
progression and relevant toxicity during the standard course
of 59,4–60Gy, a PTV-2 was created on GTV adding a
margin of 5mm; also, this boost was delivered with standard
fractionation (2Gy/day for 5 days per week).
Chemotherapy. All patients received also TMZ, concurrently
administered per os during RT, according to Stupp’s protocol
(daily TMZ 75mg/m2 during the RT course, for 6 weeks in
SDRT and for 7 weeks in HDRT), followed by the sequential
TMZ schedule (150–200mg/m2 for 5 days every 28 days) until
disease progression or complete response after 12 cycles.
2.5. Follow-Up. After the completion of RT and concurrent
TMZ administration, patients entered a scheduled follow-up
program. Brain MRI scans were repeated at 4 weeks, 12–16
weeks, and then every 6 months or in any case showing
clinical signs suggesting progressive disease (PD). Taking
into account the fact that no patient of this series received
antiangiogenic treatment, PD after RT-TMZ treatment was
assessed using the RANO Criteria [13]. A diagnosis of
pseudoprogression was made in cases showing an increase
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Figure 1: Anatomical distribution and GTV volume (expressed in cm3) of GB lesions treated with different RT dose scheme (chi-square test;
𝑝 = 0,41) in methylated (a) and unmethylated (b) patients.
in tumor size and/or T1-contrast enhancement within 3–6
months after the end of concomitant RT-TMZ, without
worsening of neurological status and with stabilization or
resolution in subsequent further MRIs studies. Imaging
findings suggestive of radionecrosis were recorded. All the
MRI examinations were revised for the compilation of this
paper by a neuroradiologist (AC). General and neurological
examinations and blood counts and chemistry were obtained
every three months.
2.6. Analyzed Parameters, Survival End-Points, and Statistical
Analysis. All the considered parameters were categorized
as follows: patients’ age at diagnosis (<50 ys and >50 ys),
KPS (100–80 and = 70); extent of surgery (GTR: gross total
resection; B-STR: biopsy or subtotal resection),MGMTstatus
(methylated and unmethylated); RT dose (SDRT, 59,4–60Gy,
and HDRT, 69,4–70Gy). In order to reduce bias selection
due to the retrospective setting of analysis, we performed
a cross-tab analysis (chi-square test) according to age, KPS,
extent of surgery, tumor location,MGMTmethylation status,
and radiological response of SDRT-TMZ versus HDRT-TMZ
patients groups.
We estimated PDFS and OS with the Kaplan-Meier
method.The univariate survival analysis was used to identify
the prognostic parameters.We used the log-rank test to assess
the significance of survival differences for the considered
parameters (𝑝 values ≤ 0,05 were considered as statistically
significant). We also performed a multivariate analysis (Cox
regression) to quantify the relationship between survival
and potential predictors, in order to identify a subgroup
of independent factors significantly related to survival. All
the statistical analyses were performed with the SPSS 15.0
software package for Windows.
3. Results
Out of the 117 patients selected for this study, the MGMT
promoter methylation status was, respectively, methylated
(methMGMT) and unmethylated (unmethMGMT) in 48
(41%) and in 69 patients (59%).
The median OS of this whole series was 13 months, OS
rate at 6 months and at 12 months being, respectively, 82,6%
and 54,4%. Median PDFS was 9 months, with 6-month and
12-month rates of 62,6% and 38,7%, respectively.
Statistically significant prognostic factors for OS and
PDFS at the univariate analysis were KPS, extent of surgical
resection, and MGMT status (Table 1).
The multivariate analysis confirmed that KPS = 70 (HR:
2,424; 95% CI: 1,082–3,652; 𝑝 = 0,001) and B-STR (HR:
1,783; 95% CI: 1,451–4,449; 𝑝 = 0,001) and unmeth-MGMT
status (HR: 3,088; 95% CI: 1,887–5,054; 𝑝 = 0,001) were
independently associated with a shorter OS and PDFS. Out
of the whole series, in HDRT-TMZ and SDRT-TMZ groups,
the median OS and PDFS times were similar: 12 months and
4 BioMed Research International
Table 1: Clinical (age = age at diagnosis, KPS =Karnofsky Performance Status), treatment (GTR =macroscopic gross total resection, B/STR =
biopsy or subtotal tumor resection, dose RT = total dose for radiotherapy treatment, HDRT = 70Gy, and SDRT = 59,4–60Gy), and biological
(MGTM) prognostic factors (Kaplan-Meier method, survival analysis).
Number of patients OS 𝑝 value PDFS 𝑝 value
Median (months) Median (months)
Age >50 100 12 0,09 9 0,30
<50 17 17 9
KPS 100–80 106 14 0,001 9 0,018
=70 11 7 4
Extent of surgery GTR 32 22 0,02 12 0,005
B/STR 85 11 7
MGMT status Methylated 48 25 0,0001 15 0,001
Unmethylated 69 11 7
RT DOSE HDRT 45 14 0,22 10 0,12
SDRT 72 12 7
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Figure 2: Overall Survival (a) and Progression-Disease Free Survival (b) (Kaplan-Meier method) according to standard (SDRT-TMZ) versus
escalated (HDRT-TMZ) RT dose (log-rank test 𝑝 value < 0,05) in unmethylated patients.
7 months for the SDRT-TMZ group and 14 months and 10
months for the HDRT-TMZ group.
A subgroup survival analysis for MGMT methylation
status and extent of resection was performed. In unmeth-
MGMT patients (48 pts), HDRT-TMZ and SDRT-TMZ
groups had different median OS (𝑝 = 0,01) and PDFS
(𝑝 = 0,007): 8 months and 5 months for the SDRT-TMZ
group and 14 months and 9 months for the HDRT-TMZ
group, respectively (Figure 2). No difference in OS and PDFS
between HDRT-TMZ and SDRT-TMZ groups was found
according to residual disease. Conversely, different OS (𝑝 =
0,001) and PDFS (𝑝 = 0,005) between HDRT-TMZ and
SDRT-TMZ schemes, respectively, were found in unmeth-
MGMT patients group with macroscopic residual disease
(B/SRT) (Figure 3).
TheRTdosewas confirmed as an independent prognostic
factor at multivariate analysis in unmeth-MGMT patients
unadjusted (HR: 2,090; CI 95%: 1,151–3,795) and adjusted
for extent of resection (HR 2,807; CI 95%: 1,186–4,567). No
significant difference in distribution of the other prognostic
factors was found between these two groups (Table 2). In
terms of radiological response, the HDRT-TMZ group had
a better response compared to the SDRT-TMZ one: an
objective response (complete response + partial response)
was demonstrated in 51,5% (14/33) and 13,9% (5/36) cases,
respectively (𝑝 = 0,031, Table 2).
Differently, no difference in survival outcomes was found
in meth-MGMT patients according to the different RT-TMZ
schemes used (for OS: 𝑝 = 0,12 and for PDFS: 𝑝 = 0,23),
even when analyzed by extent of surgical resection (data not
reported).
4. Discussion
The treatment standard of GB includes maximal safe surgical
resection followed by RT with concurrent and sequential
TMZ (RT-TMZ) [1].
Response to treatment depends on the methylation status
of the promoter ofMGMT. In clinical practice, MGMT status
is presently one of the most important biomarkers for prog-
nostic stratification of GB patients, along with other molec-
ular features, such as Isocitrate Dehydrogenase 1 (IDH1)
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Figure 3: Overall Survival (a) and Progression-Disease Free Survival (b) (Kaplan-Meier method) according to standard (SDRT-TMZ) versus
escalated (HDRT-TMZ) RT dose (log-rank test 𝑝 value < 0,05) in unmethylated patients with incomplete resection.
Table 2
(a) HDRT-TMZ and SDRT-TMZ patient’s characteristic in methylated group (𝑛 = 48)
HDRT patients (𝑛 = 12) SDRT patients (𝑛 = 36) Chi-square significance
KPS 100–80 12 32 𝑝 = 0,67
=70 0 4
Extent of resection GRT 6 10 𝑝 = 0,53
B/SRT 6 26
Age >50 ys 11 27 𝑝 = 0,33
<50 ys 1 9
Radiological response
Complete response 6 9
𝑝 = 0,65Partial response 3 6
Stable disease 1 9
Progression disease 2 12
Radionecrosis 1 1 𝑝 = 0,78
(b) HDRT-TMZ and SDRT-TMZ patient’s characteristic in unmethylated group (𝑛 = 69)
HDRT patients (𝑛 = 33) SDRT patients (𝑛 = 36) Chi-square significance
KPS 100–80 30 32 𝑝 = 0,35
=70 3 4
Extent of resection GRT 9 7 𝑝 = 0,56
B/SRT 24 29
Age >50 ys 29 33 𝑝 = 0,46
<50 ys 4 3
Radiological response
Complete response 7 3
𝑝 = 0,031Partial response 7 2
Stable disease 7 6
Progression disease 12 25
Radionecrosis 1 0 𝑝 = 0,8
mutational status, which are presently considered of the same
clinical relevance [14, 15]. The MGMT promoter methyla-
tion status is associated not only with a different response
(PDFS, OS) to RT-TMZ, but also with either treatment
modality alone [7]. Meth-MGMT GB patients with a good
performance status (ECOG 0-1) have a considerable response
to RT-TMZ treatment. One study reports a median survival
of 24.7 (ECOG 0)–16.4 (ECOG 1) months and a 2-year
survival rate of 66–48,1%, whereas the corresponding results
for unmeth-MGMT GBs are 12,9 (ECOG 0)–9,7 (ECOG 1)
months and 2-year survival rates of 31% and 14,6%, respec-
tively [16]. Considering that 90% of relapse occurs in the
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primary site, especially in unmeth-MGMT GB patients [17],
this subgroup may theoretically benefit from increased RT
dose schedules. The neurooncological community presently
accepts a RTdose prescription of 60Gy inRT-TMZ treatment
of GB, delivered with conformal external beam techniques on
partial-brain volumes, in five weekly fractions of 1,8–2,0Gy
[1]. However, mathematical modeling previsions consider
the possibility of a substantially improved local control of
GB with intensified dose-fractionation schedules [18]. In the
clinical setting, this possibility has been widely investigated
with unclear results. Tanaka et al. compared 60 and61 patients
with GBM who received 60Gy and 80–90Gy conformal RT,
respectively, and suggested a survival benefit for patients
treated with high dose [19], but most experiences failed to
demonstrate a benefit for RT doses > 60Gy delivered with
external beam techniques [20, 21]. Also hypofractionation
(often without TMZ chemotherapy) [22, 23] or other RT
techniques, such as brachytherapy [24] or radiosurgery (SRS)
[25], did not give appreciable results. A previous experi-
ence of our institution [9] with a protocol-driven RT-TMZ
schedule and high-dose stereotactic radiation boost included
123 patients, 25 of whom received 70Gy on a reduced
volume, after a selection based on tumor size (≤5 cm major
diameter). This series included also a minority of anaplastic
astrocytomas; however, out of the 18GBs that received 70Gy
boost, 2- and 3-year OS results were 39% and 22%. This
treatment was well tolerated and no high-grade complication
was detected during the follow-up, even if no systematic
attempt was made for the diagnosis of asymptomatic brain
RT damage. Based on this experience, assuming a potential
and safe improvement in the treatment effectiveness by
escalating the total RT dose without increasing the frac-
tion size in selected patients, we continued to adopt this
treatment protocol and analyzed the achieved results in the
present study. Out of the overall selected series of 117GB
patients, the dose escalation (HDRT-TMZ) did not improve
the survival outcomes. Retrospectively adopting a prognostic
stratification according to the MGMT methylation status,
we also found that PDFS and OS results of meth-MGMT
patients were not influenced by the effect of HDRT-TMZ.
In unmeth-MGMT patients, instead, the use of HDRT-TMZ
schedule significantly improved both PDFS (𝑝 = 0,007) and
OS (𝑝 = 0,01), compared to SDRT-TMZ. This finding did
not seem to be related to a different distribution of the HD
versus SDRT patients’ characteristics in terms of age, extent
of resection, and lesion localization (shown in Table 2(a)).
However, the survival advantage seems to be related to a good
treatment response, as shown by the radiological evaluation
after treatment in HDRT-TMZ group (Table 2(a)). In these
patients, the effect of HDRT in terms of survival gain is
particularly significant when an extensive surgical resection
was not accomplished. This is in contrast with the widely
reported experience that the extent of residual disease after
surgery is related to prognosis and patients with incomplete
resections fared worse than those macroscopically resected
[26, 27]. This generally agreed statement was the subject of a
recent, very sophisticated analysis [28], showing that for any
GB patient each prognostic covariate (i.e., age, KPS, extent of
resection, and RT and TMZ treatment accomplishment) may
have a predictive impact on survival. It could be expected,
on these grounds, that the RT dose escalation up to 70Gy
(and perhaps the prolongation for a week of the concurrent
TMZ-RT administration in unmeth-MGMT patients) may
demonstrate a positive influence on local control of the
disease and survival, especially when its influence is not
covered up by the major effect of a macroscopically complete
surgical resection.This possibility seems compatible with our
results.
5. Limitations of the Study
The retrospective design, the adopted selection criteria, and
the small number of patients are some pitfalls of the present
analysis. IDH assessment was not reported because it was not
performed across all patients. Lacking IDH assessment, even
in presence of a small number of secondary glioblastomas,
could reduce prognostic stratification of present analysis.
6. Conclusions
To the authors’ knowledge, this is the first study reporting a
possible benefit for unmeth-MGMT GB population from a
RTmoderate dose escalation with standard fractionation and
the concurrent use of TMZ. These findings deserve further
investigations and prospective trials may be devised on these
bases.
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